Last reviewed · How we verify
Vancomycin intermittent dosing interval
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea, Endocarditis.
At a glance
| Generic name | Vancomycin intermittent dosing interval |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin works by preventing cross-linking of peptidoglycan strands in the bacterial cell wall, leading to cell wall instability and bacterial death. The intermittent dosing interval refers to the clinical dosing schedule (typically every 8-12 hours) rather than a novel mechanism, optimizing drug exposure and reducing nephrotoxicity while maintaining efficacy against susceptible gram-positive organisms.
Approved indications
- Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA)
- Clostridium difficile-associated diarrhea
- Endocarditis
- Meningitis caused by susceptible organisms
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (flushing, pruritus)
- Phlebitis at infusion site
- Hypersensitivity reactions
Key clinical trials
- Continuous vs. Intermittent Infusion Vancomycin (PHASE4)
- Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2) (PHASE4)
- Antibiotic Dosing in Patients on Intermittent Hemodialysis
- Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: